Table 1.
Technical issue | Why relevant? | Considerations |
---|---|---|
Panel content | Panel size and selection of genomic loci can affect detection of copy number gains |
(i) Contains amplicons/probes sufficiently spread throughout the genome (ii) Includes loci likely to not be affected by copy number variation in tumor of interest (iii) Minimal number of amplicons/probes per gene, preferably throughout gene locus (iv) For BAF, include sufficient number of heterogeneous loci for sufficient “SNP-density” |
Normalization | Required to correct for differences in gDNA input quality/quantity | Choose method that is not/minimally affected by copy number variation |
Reference pool | Is required to detect coverage outliers indicative of copy number gains |
(i) Internal and/or external reference pool (ii) Includes samples without copy number variation (e.g., normal tissue) (iii) Processed using identical protocols |
Thresholds | Required to distinguish genuine copy number gains from technical noise |
(i) Validated by positive/negative controls using other methods (ii) Includes minimal coverage thresholds to prevent false positive calls from poor quality gDNA (iii) Include positive and negative controls on a regular basis, to ensure assay stability and test validated thresholds |
Sensitivity | Awareness of assay limitations is critical for routine diagnostics |
(i) Affected by thresholds and neoplastic cell percentage (ii) Should be included in clinical report |